pioglitazone/metformin / Generic mfg. - LARVOL DELTA

Enhancing Glycemic Control through Orlistat Combination Therapy with Pioglitazone and Metformin in Patients with Obesity Type 2 Diabetes—A Multicenter Randomized Controlled Trial (ADA 2025) - "Orlistat is effective for patients with obesity and type 2 diabetes who are receiving pioglitazone-metformin therapy, it reduces body weight, improves fat distribution, alleviates insulin resistance, and enhances glycemic control."

Clinical • Combination therapy • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Enhancing Diabetes Treatment: Comparing Pioglitazone/Metformin with Dapagliflozin Versus Basal Insulin/Metformin in Type 2 Diabetes. (PubMed, Drug Des Devel Ther) - P4 | "Patients in the test group were more satisfied than those in the control group with continuing to accept pioglitazone/metformin FDC combined with dapagliflozin. CHiCTR2000036076. https://www.chictr.org.cn/showproj.html?proj=58825."

Clinical • Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Versus Uptitrated Metformin in Patients with Type 2 Diabetes without Adequate Glycemic Control: A Randomized Clinical Trial. (PubMed, Diabetes Ther) - "Pioglitazone/metformin FDC was superior to uptitrated metformin among patients with T2DM without adequate glycemic control."

Clinical • Journal • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP

Influencing factors of stroke in patients with type 2 diabetes: A systematic review and meta-analysis. (PubMed, PLoS One) - "This study underscores the multitude of influencing factors contributing to stroke in people with T2DM patients, among which the microvascular complications of T2DM play an most important role. Therefore, we emphasize the importance of screening for microvascular complications in patients with T2DM. However, due to limitations arising from the number of articles reviewed, there remain areas where clarity is lacking. Further research efforts are warranted to expand upon and reinforce our current findings."

Clinical • Journal • Retrospective data • Review • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Diabetes • Diabetic Retinopathy • Dyslipidemia • Heart Failure • Hypertension • Metabolic Disorders • Peripheral Arterial Disease • Renal Disease • Retinal Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial. (PubMed, Clin Diabetes Endocrinol) - "The FDC of MSP demonstrated significant efficacy in managing glycemic indices and could serve as a valuable tool for physicians in the management of Indian patients with T2DM."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of pioglitazone/metformin fixed-dose formulation vs uptitrated metformin in type 2 diabetes with inadequate glycaemic control: a randomised trial (EASD 2023) - "Among T2DM patients with IGC, a 16-week oral administration of pioglitazone/metformin FDC was superior to uptitrated metformin in controlling serum glucose, modifying lipid profiles and reducing circulating inflammation level."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Combination of Pioglitazone and Metformin Actions on Liver Lipid Metabolism in Obese Mice. (PubMed, Biomolecules) - "Pioglitazone and metformin might have a synergistic protective effect on NAFLD by improving hepatic lipid profiles in HFD-induced mice. Further studies are needed to verify the clinical effects."

Journal • Preclinical • Hepatology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Obesity • CD36 • FADS2 • FASN

The MetAction project: Biomarker-directed molecularly matched therapy for end-stage cancer implemented in clinical practice. (ASCO 2017) - P2; "We will report on patient outcome (progression-free survival, overall response rate, and tolerance) to this biomarker-directed treatment in end-stage cancer."

Biomarker • Clinical • Biliary Cancer • Biosimilar • Sarcoma

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice. (PubMed, Front Pharmacol) - "Combination therapy markedly altered gut microbiota by increasing beneficial bacteria, such as Bifidobacterium, Christensenellaceae_R-7_group, Faecalibacterium and Roseburia, and decreasing harmful bacteria, such as Oscillibacter and Eubacterium_xylanophilum_group. Fecal metabolites were significantly changed in the combination therapy group, including a reduction in amino acid metabolism and augmentation of lipid metabolism, such as citrulline, sarcosine, D-glutamine, lipoxin A4, prostaglandin E2, stearidonic acid and lucidenic acid A. These results revealed that combined metformin and pioglitazone therapy had synergistic effects or at least have an additive effect on modifying gut microbiota and metabolites, closely associated with improved glucolipid metabolic parameters in HFD-fed mice, which provides novel evidence and promising targets for metformin and pioglitazone combination therapy in type 2 diabetes."

Combination therapy • Journal • Preclinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial. (PubMed, Diabetes Metab Syndr Obes) - "It is believed that the direct comparisons of the hypoglycemic effects, VAT reductions, and safety profiles between pioglitazone and sitagliptin will help to optimize treatments for Chinese adults with T2D who are primarily characterized by IR. Chinese Clinical Trial Registry (ChiCTR1900021861)."

Clinical • Combination therapy • Head-to-Head • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Serum uric acid and diabetes: from pathophysiology to cardiovascular disease. (PubMed, Curr Pharm Des) - "Furthermore, we comment on the available evidence linking elevated SUA levels with the incidence and outcomes of coronary heart disease, stroke, peripheral artery disease and non-alcoholic fatty liver in subjects with T2DM. The effects of antidiabetic drugs (e.g. metformin, pioglitazone, sulfonylureas, dipeptidyl peptidase 4 inhibitors, glucagonlike peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors and insulin) on SUA concentrations are also reviewed."

Journal • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Gout • Heart Failure • Hematological Disorders • Hepatology • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Non-alcoholic Fatty Liver Disease • Peripheral Arterial Disease • Renal Calculi • Rheumatology • Thrombosis • Type 2 Diabetes Mellitus • Urolithiasis

[VIRTUAL] Evaluation of sodium-glucose transporter 2 inhibitors in patients with non-alcoholic fatty liver disease (ASHP 2020) - "SGLT2I have been shown to be effective in combating HS by reducing imaging markers in T2DM patients with NAFLD compared with current diabetic SOC. Furthermore, improvement in NAFLD was noted when compared with diet/exercise in addition to diabetic SOC, and in patients with well-controlled diabetes. SGLT2I were not found to be superior in reducing HS when compared with pioglitazone or pioglitazone plus metformin."

Clinical • Fibrosis • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Oncology • Solid Tumor • Transplantation • Type 2 Diabetes Mellitus

[VIRTUAL] Blood pressure management in patients with type 2 diabetes mellitus in an interprofessional student-run free clinic (ASHP 2020) - "The following keywords or codes were used to identify the patients: “diabetes,” “type 2 diabetes mellitus,” “metformin,” “pioglitazone,” “glipizide,” glyburide,” “insulin,” “E11.9,” and “250.” Patients with prediabetes, type 1 diabetes, or with no confirmed diagnosis of T2DM were excluded. Diabetic patients at EACN may need a more aggressive approach to manage their blood pressure. At our student-free run clinic, utilizing ASCVD risk score to determine BP goals may not be feasible given the limited supplies to provide point of care lipid panel tests. Further analysis needs to be done to assess BP management in this population in which there may be issues related to adherence and low health literacy."

Clinical • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Efficacy of Treatments for Polycystic Ovarian Syndrome Management in Adolescents. (PubMed, J Endocr Soc) - "Moderate-quality evidence showed hirsutism scores were reduced by multiple interventions that included single and combination medications namely; lifestyle intervention, metformin, OCP, spironolactone, pioglitazone, metformin-OCP, metformin-spironolactone, and metformin-flutamide against placebo. Further research into new treatment options is urgently needed. CRD42015016148."

Clinical • Journal • Review • Polycystic Ovary Syndrome • Women's Health

Accelerated diabetic wound healing by topical application of combination oral antidiabetic agents-loaded nanofibrous scaffolds: An in vitro and in vivo evaluation study. (PubMed, Mater Sci Eng C Mater Biol Appl) - "The combination therapy increased the wettability and hydrophilicity of scaffolds, demonstrated sustained drug release over 14 days, has high tensile strength and suitable cytocompatibility on L929 (mouse fibroblast) cell and created a suitable area for the proliferation of fibroblast cells. Consequently, the application of metformin and pioglitazone-loaded chitosan/gelatin/PCL nanofibrous scaffolds to a diabetic wound area offer high bioavailability, fewer systemic side effects, and reduced frequency of dosage and amount of drug."

Journal • Preclinical • Diabetes • Type 1 Diabetes Mellitus

Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature. (PubMed, Diabetes Metab Syndr) - "Metformin and DPP-4i should be continued in patients with T2DM until hospitalization or unless contraindicated. No evidence of harm suggests that SUs, SGLT-2i or GLP-1RAs may not be stopped unless very sick, hospitalized or contraindicated. The results from RCTs are needed to claim any meaningful benefit with either metformin or DPP-4i in patients with T2DM and COVID-19."

Clinical • Journal • Review • Diabetes • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

Evaluation of the prevention by pioglitazone/metformin of ER-positive and ER-negative mammary cancers occurring in rodents on a high-fat diet (AACR 2018) - "Actoplus/Met, a combination of the two agents, is currently used in the clinic with an additive effect on improving insulin resistance, a proposed risk factor for certain cancers. (4) Metformin showed some chemopreventive efficacy when given alone to MMTV/Neu mice receiving DMBA and on a high-fat diet. Efficacy was also observed with metformin alone and in combination with pioglitazone in mice receiving a high-fructose diet."

Preclinical • Hormone Receptor Breast Cancer

Potential chemopreventative treatments in Fanconi anemia related HNSCC (AACR 2018) - "...Pioglitazone (10 M) and metformin (above 1 mM) resulted in larger, cell line dependent, decreases in cell proliferation than either agent alone...Further studies are underway to evaluate the relative contribution of HBB to decreased cell proliferation versus apoptotic mechanisms. Recent studies of HBB in breast cancer indicate cytochrome P450 arachidonic acid epoxygenase activity as an HBB target and suggest further exploration of this target in head and neck squamous cell carcinoma."

Breast Cancer • Oral Cancer

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. (PubMed, Cochrane Database Syst Rev) - "Pioglitazone reduced or delayed the development of T2DM in people at increased risk of T2DM compared with placebo (low-certainty evidence) and compared with no intervention (moderate-certainty evidence). It is unclear whether the effect of pioglitazone is sustained once discontinued. Pioglitazone compared with metformin neither showed advantage nor disadvantage regarding the development of T2DM in people at increased risk (low-certainty evidence). The data and reporting of all-cause mortality, SAEs, micro- and macrovascular complications were generally sparse. None of the included studies reported on QoL or socioeconomic effects."

Journal • Review • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. (PubMed, Diabetes Care) - "Triple therapy with agents that improve insulin sensitivity and β-cell function in patients with new-onset T2DM produce greater, more durable HbA reduction than agents that lower glucose levels without correcting the underlying metabolic defects."

Clinical • Combination therapy • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Low Circulating Levels of miR-451a in Girls with Polycystic Ovary Syndrome: Different Effects of Randomized Treatments. (PubMed, J Clin Endocrinol Metab) - "We studied the baseline microRNA (miRNA) profile of girls with PCOS, and the effects of a randomized treatment with an oral contraceptive (OC) or with spironolactone-pioglitazone-metformin (SPIOMET, aiming at loss of hepato-visceral fat excess) for 1 year. SPIOMET treatment for 1 year normalizes the miRNA profile of girls with PCOS. Circulating miR-451a may become a biomarker to guide the diagnosis and treatment of PCOS in adolescence."

Clinical • Journal • Diabetes • Infertility • Metabolic Disorders • Polycystic Ovary Syndrome • Type 2 Diabetes Mellitus

[VIRTUAL] The effects of metformin, pioglitazone and empagliflozin on metabolic control, hormonal imbalance, weight loss and ovulations in obese patients with polycystic ovary syndrome and impaired glucose tolerance (ISGE-I 2020) - "Metformin,Pioglitazone and Empagliflozin were equally efficient in regulating menstrual cycles in patients with PCOS.Pioglitazone and Empagliflozine were superior to metformin in metabolic control while metformin was superior in resolving hyperandrogenism.Pioglitazone and Empagliflozin can be a second therapy of choice in patients with PCOS."

Clinical • Obesity • Polycystic Ovary Syndrome • LEP

Gut microbiota in adolescent girls with polycystic ovary syndrome: Effects of randomized treatments. (PubMed, Pediatr Obes) - "SPIOMET's spectrum of normalizing effects in girls with PCOS is herewith broadened as to include Family XI abundance in gut microbiota."

Clinical • Journal • Genetic Disorders • Obesity • Polycystic Ovary Syndrome

"Should be used 5th line in Diabetic patients without symptoms. SGLT-2, GLP-1, pioglitazone and metformin prior to weekly insulin" (@DrMetabolism)

Clinical • Diabetes • Metabolic Disorders

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) (clinicaltrials.gov) - P=N/A; N=700; Recruiting; Sponsor: The University of Texas Health Science Center at San Antonio; Trial completion date: Jul 2023 ➔ Jul 2024; Trial primary completion date: Jul 2022 ➔ Jul 2023

Clinical • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus